top of page

GPCR News 

Post: Blog2_Post
Writer's pictureGPCR News

Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer

May 2022


"MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately.


Mr. Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences industry. Before joining Inversago, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised follow-on capital later that same year. Prior to that, Mr. Vraniak served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management team that led the company through a successful IPO on Nasdaq in June 2018. Additionally, Mr. Vraniak served as an executive in various innovative healthcare and technology companies including GE Capital, where he served as Executive Vice President." Read more at the source

2 views0 comments

Recent Posts

See All

Comments